Journal: International Journal of Molecular Sciences

Article Title: Extensive Histopathological Characterization of Inflamed Bowel in the Dextran Sulfate Sodium Mouse Model with Emphasis on Clinically Relevant Biomarkers and Targets for Drug Development

doi: 10.3390/ijms22042028

Figure Lengend Snippet: List of antibodies used in the study.

Article Snippet: anti-IL-17A , Rat monoclonal, clone TC11-18H10; Novus Biologicals, Littleton, CO, USA , 1:50 , EDTA–Citrate pH 7.8.

Techniques:

Journal: Experimental & Molecular Medicine

Article Title: Discovery of ETI41 and ETI60: novel selective endosomal Toll-like receptor inhibitors for the treatment of autoimmune diseases

doi: 10.1038/s12276-025-01526-w

Figure Lengend Snippet: a Psoriasis was induced in female C57BL/6J mice by topically applying IMQ (62.5 mg/cm 2 ). ETI41 and ETI60 were orally administered daily at a dose of 60 mg/kg. b Impact of ETI41 and ETI60 on body weight during treatment. c PASI score indicating disease severity. d Images of the back skin of mice were captured on the fifth day of treatment, revealing the therapeutic efficacy of ETI41 or ETI60 compared with the normal and untreated groups. Immunohistochemical staining of back skin sections from each group revealed the effects of ETI41 and ETI60 on thickness of the epidermis (yellow arrowhead) and dermis (green arrowhead). e The thickness of the epidermis and dermis, as well as the expression levels of CD68 (a macrophage marker), Ki-67, IL-17A and IL-23, were measured. f Psoriasis was induced in female C57BL/6J mice by injecting IL-23 (500 ng) into their ear skin. Anti-IL17A antibody (Ab, 60 µg) was administered by IP injection as a positive control on days 2, 5 and 8. ETI41 or ETI60 was administered orally at a daily dose of 60 mg/kg for 9 days. g Body weight was recorded during treatment. h On the ninth day of treatment, images of the mouse ears were acquired to demonstrate the therapeutic efficacy of ETI41 and ETI60 in comparison with the normal, vehicle or anti-IL17 groups. CD68 and Ki-67 expression patterns were determined in skin sections from a representative of each group using immunofluorescence. i Ear skin and epidermis thickness, CD68 expression and percentage of Ki-67 cells were examined from 4’,6-diamidino-2-phenylindole-stained cells. Statistical differences between the induced case and other cases were analyzed and verified using a one-tailed Student’s t -test (* P < 0.05, ** P < 0.01, *** P < 0.001).

Article Snippet: Immunohistochemical analyses were performed using primary antibodies against CD68 (R&D Systems, MAB101141), Ki-67 (Cell Signaling Technology, 12202), IL-17A (Novus Biologicals, NBP1-72027) and IL-23 (Novus Biologicals, NBP1-76697), followed by detection using biotinylated secondary antibodies (Vector Laboratories) and diaminobenzidine (Vector Laboratories) visualization.

Techniques: Drug discovery, Immunohistochemical staining, Staining, Expressing, Marker, Injection, Positive Control, Comparison, Immunofluorescence, One-tailed Test